Association of Systemic Sclerosis With a Unique Colonic Microbial Consortium
Objective To compare colonic microbial composition in systemic sclerosis (SSc) patients and healthy controls and to determine whether certain microbial genera are associated with gastrointestinal (GI) tract symptoms in patients with SSc. Methods Healthy controls were age‐ and sex‐matched (1:1) with...
Saved in:
Published in | Arthritis & rheumatology (Hoboken, N.J.) Vol. 68; no. 6; pp. 1483 - 1492 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Wiley Subscription Services, Inc
01.06.2016
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Objective
To compare colonic microbial composition in systemic sclerosis (SSc) patients and healthy controls and to determine whether certain microbial genera are associated with gastrointestinal (GI) tract symptoms in patients with SSc.
Methods
Healthy controls were age‐ and sex‐matched (1:1) with adult SSc patients. Cecum and sigmoid mucosal lavage samples were obtained during colonoscopy. The microbiota in these samples were determined by Illumina HiSeq 2000 16S sequencing, and operational taxonomic units were selected. Linear discriminant analysis effect size was used to identify the genera that showed differential expression in SSc patients versus controls. Differential expression analysis for sequence count data was used to identify specific genera associated with GI tract symptoms.
Results
Among 17 patients with SSc (88% female; median age 52.1 years), the mean ± SD total GI Tract 2.0 score was 0.7 ± 0.6. Principal coordinate analysis illustrated significant differences in microbial communities in the cecum and sigmoid regions in SSc patients versus healthy controls (both P = 0.001). Similar to the findings in inflammatory disease states, SSc patients had decreased levels of commensal bacteria, such as Faecalibacterium and Clostridium, and increased levels of pathobiont bacteria, such as Fusobacterium and γ‐Proteobacteria, compared with healthy controls. Bifidobacterium and Lactobacillus, which are typically reduced under conditions of inflammation, were also increased in abundance in patients with SSc. In SSc patients with moderate/severe GI tract symptoms, the abundance of Bacteroides fragilis was decreased, and that of Fusobacterium was increased, compared with patients who had no or mild symptoms.
Conclusion
This study demonstrates a distinct colonic microbial signature in SSc patients compared with healthy controls. This unique ecologic change may perpetuate immunologic aberrations and contribute to clinical manifestations of SSc. |
---|---|
Bibliography: | Dr. Conklin has received speaking fees from Medtronic (less than $10,000). Dr. Furst has received consulting fees from AbbVie, Actelion, Amgen, Bristol‐Myers Squibb, Cytori, Janssen, Gilead, GlaxoSmithKline, Novartis, Pfizer, Roche/Genentech, and UCB (less than $10,000 each). Supported by the USPHS (grant DK‐046763 to Drs. McGovern and Braun, grants DK‐062413, AI‐067068, U54‐DE‐023789‐01, and HS‐021747 to Dr. McGovern, and grant AI‐078885 to Dr. Braun), the National Center for Advancing Translational Science, NIH (award UL1‐TR‐000124), and the Helmsley Charitable Trust and the Crohn's and Colitis Foundation of America (grants to Drs. Borneman, McGovern, and Braun). Dr. Volkmann's work was supported by the Specialty Training and Advanced Research Program at the University of California, Los Angeles David Geffen School of Medicine. Dr. McGovern's work was supported by the Fineberg Foundation, the Cedars‐Sinai F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, and the European Union (grant 305479); he also holds the Joshua L. and Lisa Z. Greer Chair in Inflammatory Bowel Disease Genetics at Cedars‐Sinai Medical Center. Dr. Jacobs’ work was supported by the NIH (grant T32‐DK‐07180‐39). ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 2326-5191 2326-5205 |
DOI: | 10.1002/art.39572 |